PMID- 15626448
OWN - NLM
STAT- MEDLINE
DCOM- 20050712
LR  - 20161124
IS  - 0142-9612 (Print)
IS  - 0142-9612 (Linking)
VI  - 26
IP  - 18
DP  - 2005 Jun
TI  - Collagen-chondroitin sulfate-based PLLA-SAIB-coated rhBMP-2 delivery system for 
      bone repair.
PG  - 4023-34
AB  - Bone morphogenetic proteins (BMPs) are osteoinductive proteins used intensively 
      in clinical investigations involving various bone-related treatments. Owing to 
      their high potential in new bone formation they require local application at the 
      treatment site. For this purpose various controlled delivery systems with BMPs as 
      the excipients have been prepared in recent years. Focusing on this clinical need 
      a disc-shaped BMP carrier was designed as a local delivery system using soluble 
      collagen and chondroitin sulfate. In situ release studies carried out with a 
      model protein (FITC-labeled Protein A) presented a very high rate of release; 
      with most of the protein content being released within 24 h. This rate could be 
      decreased by providing a poly(L-lactide) (PLLA) and sucrose acetate 
      isobutyrate-based (SAIB-based) coat around the release system, applied after BMP 
      loading. In this way, it was possible to extend the release period from 24 h to 
      about 12 days. In situ release of BMP from the same carriers, as quantitated 
      using an ELISA kit, was even slower, with 50% of the protein being released in 15 
      days. In order to be able to secure the BMP delivery system at the bone defect 
      site and to provide support a mesh knitted using Vicryl sutures and bonded with 
      poly(L-lactide-co-glycolide) (PLGA) was tested in in vivo. Two time periods, 1 
      and 3 weeks, were used to evaluate the healing process. Osteoinduction by the BMP 
      carrier system was assessed by histology-based bone scoring and X-ray 
      examinations. PLLA-SAIB-coated collagen discs containing BMP presented good 
      biocompatibility and optimum osteogenic stimulation. Structural changes in 
      histological micrographs at week 1 indicated dose-dependent periosteal 
      ossification. At the end of week 3 histological findings with both BMP (1 and 2 
      microg) doses were almost the same.
FAU - Keskin, Dilek Sendil
AU  - Keskin DS
AD  - Department of Engineering Sciences, Middle East Technical University, 06531 
      Ankara, Turkey.
FAU - Tezcaner, Aysen
AU  - Tezcaner A
FAU - Korkusuz, Petek
AU  - Korkusuz P
FAU - Korkusuz, Feza
AU  - Korkusuz F
FAU - Hasirci, Vasif
AU  - Hasirci V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Biomaterials
JT  - Biomaterials
JID - 8100316
RN  - 0 (Bmp2 protein, rat)
RN  - 0 (Bone Morphogenetic Protein 2)
RN  - 0 (Bone Morphogenetic Proteins)
RN  - 0 (Coated Materials, Biocompatible)
RN  - 0 (Collagen Type I)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Polyesters)
RN  - 0 (Polymers)
RN  - 0 (Transforming Growth Factor beta)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 459TN2L5F5 (poly(lactide))
RN  - 57-50-1 (Sucrose)
RN  - 9007-28-7 (Chondroitin Sulfates)
RN  - H5KI1C3YTV (sucrose acetate isobutyrate)
SB  - IM
MH  - Animals
MH  - Bone Morphogenetic Protein 2
MH  - Bone Morphogenetic Proteins/*administration & dosage/chemistry
MH  - Bone Regeneration/drug effects
MH  - Chondroitin Sulfates/*chemistry
MH  - Coated Materials, Biocompatible/administration & dosage/chemistry
MH  - Collagen Type I/*chemistry
MH  - Delayed-Action Preparations/*administration & dosage/chemistry
MH  - Diffusion
MH  - Elasticity
MH  - Femoral Fractures/diagnosis/*drug therapy
MH  - Fracture Healing/*drug effects
MH  - Hardness
MH  - Lactic Acid/*chemistry
MH  - Male
MH  - Materials Testing
MH  - Polyesters
MH  - Polymers/*chemistry
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sucrose/*analogs & derivatives/*chemistry
MH  - Tensile Strength
MH  - Transforming Growth Factor beta/*administration & dosage/chemistry
MH  - Treatment Outcome
EDAT- 2005/01/01 09:00
MHDA- 2005/07/13 09:00
CRDT- 2005/01/01 09:00
PHST- 2004/07/15 00:00 [received]
PHST- 2004/09/28 00:00 [accepted]
PHST- 2005/01/01 09:00 [pubmed]
PHST- 2005/07/13 09:00 [medline]
PHST- 2005/01/01 09:00 [entrez]
AID - S0142-9612(04)00902-0 [pii]
AID - 10.1016/j.biomaterials.2004.09.063 [doi]
PST - ppublish
SO  - Biomaterials. 2005 Jun;26(18):4023-34. doi: 10.1016/j.biomaterials.2004.09.063.